Cushing’s syndrome: diagnostic labyrinths

In the practice of a doctor of any specialty, patients with hypercorticism – a syndrome of excess glucocorticoids level in the body – are not uncommon. Despite the fact that most of these patients have characteristic appearance and clinical manifestations, the correct diagnosis is often established months or even years after the first complaints.

The objective of this article was to demonstrate the clinical cases of patients with hypercorticism of various genesis, as well as a short theoretical reference based on the National Guidelines for the Management of Patients with Cushing’s Syndrome (2016).

1. Artemova E. V. Osobennosti sinteza, aktivatsii i dezaktivatsii glyukokortikoidov. Biologicheskaya rol’ kortizola v metabolicheskikh narusheniyakh. Ozhirenie i metabolizm. 2017;(2). (In Russ.).

2. Rask E., Walker B. R., Söderberg S. et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: Increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab. 2002;87(7):3330–3336. Doi: 10.1210/jc.87.7.3330.

3. Espinosa-de-Los-Monteros A. L., Sosa E., Martinez N., Mercado M. Persistence of Cushing’s disease symptoms and comorbidities after surgical cure: a long-term, integral evaluation. Endocr Pract. 2013;19(2):252–258. Doi: 10.4158/EP12247.

4. Sharma S. T., Nieman L. K., Feelders R. A. Comorbidities in Cushing’s disease. Pituitary. 2015;18(2):188–194. Doi: 10.1007/s11102-015-0645-6.

5. Holmes K., Roberts O. L., Thomas A. M., Cross M. J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19:2003–2012. Doi: 10.1016/j.cellsig.2007.05.013.

6. Volz A. C., Huber B., Schwandt A. M. EGF and hydrocortisone as critical factors for the co-culture of adipogenic differentiated ASCs and endothelial cells. Differentiation. 2017 May–Jun;95:21–30. Doi: 10.1016/j.diff.2017.01.002.

7. Shi Y., Shu B., Yang R. et al. Wnt and Notch signaling pathway involved in wound healing by targeting c-Myc and Hes1 separately. Stem Cell Res Ther. 2015;6(1):120. Doi: 10.1186/s13287-015-0103-4.

8. Nieman L. K., Biller B. M. K., Finding J. W. et al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. Clin. Endocrinol. Metab. 2008; 93:1526–1540. Doi: 10.1210/jc.2008-0125.

9. Bolezn’ Itsenko-Kushinga. Dedov I. I., Mel’nichenko G. A., eds. Moscow, UP Print, 2012:342. (In Russ.).

10. Belaya Zh. E., Rozhinskaya L. Ya., Dragunova N. V. et al. Metabolicheskie oslozhneniya endogennogo giperkortitsizma. Vybor patsientov dlya skrininga. Ozhirenie i Metabolizm. 2013;(1):29–34. (In Russ.).

11. Valasi E., Santos A., Yaneva M. et al. The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. European J Endocrinology. 2011;165:383–392. Doi: 10.1530/EJE-11-0272.

12. Endokrinologiya. Natsional’noe rukovodstvо. Dedov I. I., Mel’nichenko G. A., eds. 2-nd edition. Moscow, GEOTAR-Media, 2016:828. (In Russ.).

13. Diez-Perez A., Hooven F. H., Adachi J. D. et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2011;49:493–498. Doi: 10.1016/j.bone.2011.05.007.

14. Dedov I. I., Belaya Zh. E., Sitkin I. I. et al. Znachenie metoda selektivnogo zabora krovi iz nizhnikh kamenistykh sinusov v differentsial’noi diagnostike AKTG-zavisimogo giperkortitsizma. Problemy Endokrinologii. 2009;(55):35–40. (In Russ.).

15. Hall W. A., Luciano M. G., Doppman J. L. et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Annual Internal Medicine. 1994;120:817–820.